We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Potential Drug Target Identified in Mouse Pancreatic Cancer Model

By LabMedica International staff writers
Posted on 19 May 2014
Print article
Cancer researchers studying pancreatic cancer (pancreatic ductal adenocarcinoma or PDAC) have identified Yes-associated protein (YAP) as a potential drug target whose inhibition would block the activity of the KRAS oncogene.

PDAC is an aggressive cancer with poor survival rates that frequently carries an oncogenic KRAS mutation. The protein product of the normal KRAS (Kirsten rat sarcoma viral oncogene) gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.

YAP-1 is a transcriptional coactivator and its proliferative and oncogenic activity is driven by its association with the TEAD family of transcription factors, which upregulate genes that promote cell growth and inhibit apoptosis. Two splice isoforms of the YAP gene product were initially identified, named YAP1-1 and YAP1-2, which differed by the presence of an extra 38 amino acids that encoded the WW domain. Apart from the WW domain, the modular structure of YAP1 contains a proline-rich region at the very amino terminus, which is followed by a TID (TEAD transcription factor interacting domain). Next, following a single WW domain, which is present in the YAP1-1 isoform, and two WW domains, which are present in the YAP1-2 isoform, there is the SH3-BM (Src Homology 3 binding motif). Following the SH3-BM is a TAD (transcription activation domain) and a PDZ domain-binding motif (PDZ-BM).

Investigators at Georgetown University (Washington DC, USA) worked with several different mouse models that had been genetically engineered to have specific KRAS mutations with or without an additional mutation in the p53 gene.

Based on the prior observation that the abundance of YAP mRNA, which encodes Yap, a protein regulated by the Hippo pathway during tissue development and homeostasis, was increased in human PDAC tissue compared with that in normal pancreatic epithelia, the investigators blocked YAP gene activity in the KRAS mutant mice.

They reported in the May 6, 2014, online edition of the journal Science Signaling that when YAP was deleted from the pancreas in these mouse models, the progression of early neoplastic lesions to PDAC was halted without affecting normal pancreatic development and endocrine function. Thus, while suppressing YAP did not prevent pancreatic cancer from first developing, it stopped any further growth.

"We believe this is the true Achilles heel of pancreatic cancer, because knocking out YAP crushes this really aggressive cancer. This appears to be the critical switch that promotes cancer growth and progression," said senior author Dr. Chunling Yi, assistant professor of oncology at Georgetown University. "The KRAS mutation uses YAP to make cancer cells grow, so shutting down YAP defuses the mutated gene's activity."

The investigators showed that YAP was critically required for the proliferation of mutant KRAS or KRAS/p53 neoplastic pancreatic ductal cells in culture and for their growth and progression to invasive PDAC in mice. "KRAS and p53 are two of the most mutated genes in human cancers, so our hope is that a drug that inhibits YAP will work in pancreatic cancer patients — who have both mutations — and in other cancers with one or both mutations," said Dr. Yi.

Related Links:

Georgetown University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Unit-Dose Packaging solution
HLX
New
UHF RFID Tag and Inlay
AD-321r6/AD-321r6-P
New
Laboratory Electric Thermostat
DNP-9025A

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more